Industry
Biotechnology
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Loading...
Open
1.09
Mkt cap
27M
Volume
30K
High
1.11
P/E Ratio
-1.85
52-wk high
2.35
Low
1.05
Div yield
N/A
52-wk low
0.53
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.